1.70
-0.58%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About OSE Immunotherapeutics
Its shares trade on Euronext Paris under the ticker OSE.PA. It has been listed since 30 March 2015. In the fiscal year to 31 December 2025, it reported revenue of €2.6m and a net loss of €37.7m. At that date it held total assets of €78.4m and shareholders' equity of €27.3m.
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire. The company went IPO on 2015-03-30. The firm develops immunotherapy products against invasive or metastatic late-stage cancers. The firm offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body’s immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient’s specific cytotoxic T response against their cancer. The Company’s main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Mar 2015
- Employees
- 42
- Website
- ose-immuno.com ↗
Leadership
Pay as last reported
- Dr. Markus CappelChairman of the Board, since 2025
- Mr. Marc Le BozecInterim Chief Executive Officer, Director, since 2025
- Mr. Thomas GidoinChief Financial Officer, Member of the Executive Committee
- Mr. Nicolas PoirierChief Scientific Officer€326,601
- Ms. Silvia ComisChief Clinic and Medical Research Officer
- Mr. Jean-Pascal ConduzorguesChief Business Officer, since 2023
- Dr. Sonya MontgomeryChief Development Officer
- Ms. Pascale BriandDirector
- Mr. Jonathan CoolDirector
- Mr. Shihong NicolaouDirector
- Mr. Alexis PeyrolesDirector, since 2016€736,592
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 22
- Environment
- 35
- Social
- 16
- Governance
- 14
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong portfolio of innovative immunotherapies.
- Advanced research and development capabilities.
- Strategic partnerships with leading pharmaceutical companies.
Weaknesses
- Limited financial resources for large-scale clinical trials.
- Relatively small market presence compared to competitors.
- Inherent risks associated with drug development and regulatory approvals.
Opportunities
- Growing demand for immunotherapies in the healthcare market.
- Expansion into emerging markets with unmet medical needs.
- Potential partnerships and collaborations for further research and development.
Threats
- Intense competition from established pharmaceutical companies.
- Evolving regulatory landscape and compliance requirements.
- Risks associated with clinical trial failures and adverse events.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.